MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'bevacizumab'. Sat, 03 Sep 2011 02:20:47 +0100 http://www.medworm.com/index.php?rid=4758709&cid=t_123598_86_f&fid=36669&url=http%3A%2F%2Ffadelibrary.wordpress.com%2F2011%2F04%2F27%2Fjournal-of-the-american-medical-association-2011-vol-305-no-5%2F The objective of this study is to perform a systematic review and meta-analysis of published randomised controlled trials (RCTs) to determine the overall risk of fatal adverse effects (FAEs) associated with bevacizumab, an angiogenesis inhibitor, used in conjunction with chemotherapy. The article concludes that in a meta-analysis of RCTs, bevacizumab in combination with chemotherapy or biological therapy, compared with chemotherapy alone, was associated with increased treatment-related mortality. An NHS Athens password is required to access this article online, alternatively contact the Library for a copy of this article Filed under: Athens Password, Current Awareness, E-Journals, Journals Tagged: Bevacizumab, Cancer, Drug Therapy, Fatal Adverse Effects, Randomised Controlled Trials (Sourc... Fade Library blogs http://www.medworm.com/rss/comments.php?id=4758709 Wed, 27 Apr 2011 10:26:16 +0100 4758709 http://www.medworm.com/index.php?rid=4592642&cid=t_123598_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F03%2F15%2F2011-nccn-conference-new-treatment-options-lead-to-steady-progress-against-ovarian-cancer%2F Recommendations stemming from recent clinical trials highlight notable updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Ovarian Cancer at the National Comprehensive Cancer Network® (NCCN®) 16th Annual Conference. Although finding effective screening tools remains a priority, new treatment options for women with ovarian cancer, such as the ones outlined in the [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4592642 Wed, 16 Mar 2011 01:20:30 +0100 4592642 http://www.medworm.com/index.php?rid=4566304&cid=t_123598_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F03%2F08%2Fohio-state-university-reports-that-ovarian-cancer-drug-bevacizumab-is-not-cost-effective%2F An analysis conducted by Ohio State University cancer researchers found that adding the targeted therapy bevacizumab to the first-line treatment of patients with advanced ovarian cancer is not cost effective. An analysis conducted by Ohio State University cancer researchers found that adding the targeted therapy bevacizumab [Avastin®] to the first-line treatment of patients with advanced [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4566304 Wed, 09 Mar 2011 00:51:51 +0100 4566304 http://www.medworm.com/index.php?rid=4277834&cid=t_123598_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Favastin-the-fdas-disappointing-decision%2F2010.12.21 “With this disappointing decision, the FDA has chosen to place itself between patients and their doctors by rationing access to a life-extending drug. . . We can’t allow this government takeover of health care to continue any longer.” That quote, courtesy of this morning’s [Dec 17th] Washington Post, incensed me to such a degree that I am writing this blog despite the two deadlines I have today. The speaker is Sen. David Vitter (R-La). The “disappointing decision” he refers to: The FDA’s decision to remove the breast cancer indication for Avastin (bevacizumab). I wrote about this earlier, and you can read the post here, but that was before yesterday’s [Dec 16th] decision. I’m not going to comment here on the benefits or risks of Avasti... Better Health blogs http://www.medworm.com/rss/comments.php?id=4277834 Tue, 21 Dec 2010 16:00:00 +0100 4277834 http://www.medworm.com/index.php?rid=4265576&cid=t_123598_83_f&fid=34856&url=http%3A%2F%2Finsidesurgery.com%2F2010%2F12%2Ffda-recommends-suspending-avastin-breast-cancer%2F The United States Food and Drug Administration is recommending that use of Avastin (bevacizumab) be suspended in the treatment of breast cancer because of too severe side effects with too little efficacy. FDA officer Dr. Janet Woodcock comments. (Source: Inside Surgery) Inside Surgery blogs http://www.medworm.com/rss/comments.php?id=4265576 Thu, 16 Dec 2010 21:00:51 +0100 4265576 http://www.medworm.com/index.php?rid=3885343&cid=t_123598_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Favastin-for-breast-cancer-will-the-fda-revoke-it%2F2010.08.19 Time to get back up on my soap box. Next month the FDA is supposed to consider taking the unique, first-time-ever step of revoking a drug’s indication not because it’s dangerous, but because it doesn’t work well enough to offset its risks. Never mind that it costs about $8,000 a month. The drug is Avastin (bevacizumab), a targeted monoclonal antibody that prevents tumors from creating and maintaining their own blood supply, a process called angiogenesis. Without oxygen and nutrients from blood, tumors can’t keep growing. Avastin is the world’s best-selling cancer drug, approved for use with chemotherapy to treat lung cancer and metastatic colorectal and breast cancer. It is also being investigated (and, likely, being prescribed off label) for numerous other c... Better Health blogs http://www.medworm.com/rss/comments.php?id=3885343 Thu, 19 Aug 2010 20:00:00 +0100 3885343 http://www.medworm.com/index.php?rid=3780355&cid=t_123598_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fbreast-cancer-diagnosis-and-treatment-can-women-trust-it%2F2010.07.22 The news wasn’t good this week for women concerned about breast cancer. First came the story that some women were diagnosed with breast cancer, very early stage, had treatment –- including disfiguring surgery -– and then found out they never had cancer in the first place. The pathologist goofed, maybe even a second pathologist also misread the biopsies. How does this happen? Not surprisingly it comes back to the clinical experience of the doctor. Properly diagnosing breast cancer, whether through radiology scans or pathology biopsies is not always easy. And in many communities the general radiologists and pathologists just don’t have enough specialized experience. This leads to mistakes, especially when the suggestions of possible cancer are subtle and minute. (more…) ... Better Health blogs http://www.medworm.com/rss/comments.php?id=3780355 Thu, 22 Jul 2010 21:00:33 +0100 3780355 http://www.medworm.com/index.php?rid=3480770&cid=t_123598_83_f&fid=34856&url=http%3A%2F%2Finsidesurgery.com%2F2010%2F04%2Fdrugs-approved-treatment-renal-cell-carcinoma-rcc%2F In the last four years, six new drugs have been approved by the United States Food and Drug Administration for the treatment of kidney cancer. They are: sorafenib, bevacizumab, sunitinib, temsirolimus, everolimus, and pazopanib (Source: Inside Surgery) Inside Surgery blogs http://www.medworm.com/rss/comments.php?id=3480770 Sat, 17 Apr 2010 17:44:04 +0100 3480770 http://www.medworm.com/index.php?rid=3338404&cid=t_123598_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F03%2F05%2Fgog-says-continuation-of-pivotal-opaxio-maintenance-therapy-trial-gog-212-remains-high-priority%2F Gynecologic Oncology Group (GOG) Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority.  GOG-218 Bevacizumab Results Do Not Influence Importance of GOG-212 Cell Therapeutics, Inc. (“CTI”) announced today that the company received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3338404 Sat, 06 Mar 2010 02:48:42 +0100 3338404 http://www.medworm.com/index.php?rid=3311889&cid=t_123598_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F02%2F25%2Fgenentech-announces-positive-results-of-avastin-phase-iii-study-in-women-with-advanced-ovarian-cancer%2F Genentech announces positive results of Avastin Phase III study (GOG 218) in women with advanced ovarian cancer. The study showed that women who continued maintenance use of Avastin alone, after receiving Avastin in combination with chemotherapy, lived longer without the disease worsening compared to those who received chemotherapy alone. This is the first Phase [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3311889 Thu, 25 Feb 2010 18:40:30 +0100 3311889 http://www.medworm.com/index.php?rid=2832371&cid=t_123598_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F09%2F24%2Fmodified-chemo-regime-increases-survival-in-advanced-ovarian-cancer-patients-but-adds-toxicity%2F Women with advanced ovarian cancer lived longer and without their tumors growing after receiving a modified regimen of a standard chemotherapy drug combination, Japanese researchers reported last week. In a large phase III clinical trial, women who received carboplatin every 3 weeks and a reduced dose of paclitaxel (Taxol®) once a week for 3 weeks [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2832371 Thu, 24 Sep 2009 20:44:57 +0100 2832371 http://www.medworm.com/index.php?rid=2719937&cid=t_123598_136_f&fid=35294&url=http%3A%2F%2Fwww.psa-rising.com%2Fblog%2F2009%2F08%2Fvegf-inhibitors-and-prostate-cancer-therapy%2F In people with cancer angiogenesis involves the growth of tiny new blood vessels to generate a blood supply for tumors. This process has been shown to play an important role in the growth, proliferation and spread of prostate cancer tumors. Vascular endothelial growth factor (VEGF) is a chemical signal produced by cells that stimulates the [...] (Source: psa-rising.com/blog) psa-rising.com/blog blogs http://www.medworm.com/rss/comments.php?id=2719937 Thu, 20 Aug 2009 14:43:53 +0100 2719937 http://www.medworm.com/index.php?rid=2512799&cid=t_123598_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F06%2F18%2F2009-asco-annual-meeting-highlights-ovarian-cancer-select-general-issues%2F The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Orlando, Florida from May 29 through June 2, 2009.  We provide below select highlights from the 2009 ASCO Annual Meeting that relate to ovarian cancer and other general issues. The 2009 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Orlando, [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2512799 Thu, 18 Jun 2009 22:11:35 +0100 2512799 http://www.medworm.com/index.php?rid=2205989&cid=t_123598_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F02%2F21%2F2009-society-of-gynecologic-oncologists-annual-meeting-ovarian-cancer-highlights%2F From February 5th through 8th, 2009, the Society of Gynecologic Oncologists’ (SGO) held its 40th Annual Meeting on Women’s Cancer in San Antonio, Texas. The meeting, viewed as the preeminent scientific and educational conference for women’s cancer care specialists, featured more than 350 scientific oral and poster presentations as well as educational sessions [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2205989 Sun, 22 Feb 2009 01:22:59 +0100 2205989 http://www.medworm.com/index.php?rid=1727802&cid=t_123598_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2008%2F08%2F03%2Fcombination-targeted-therapy-with-sorafenib-bevacizumab-shows-antitumor-activity%2F The results from a recent Phase I solid tumor clinical trial indicate that combination targeted therapy with sorafenib and bevacizumab produces anti-tumor activity (and enhanced toxicity) with respect to 43% of the ovarian cancer patients enrolled in that trial. Sorafenib (Nexavar®) inhibits the Raf kinase and vascular endothelial growth factor (VEGF) receptor. Bevacizumab (Avastin®) is [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=1727802 Mon, 04 Aug 2008 02:36:13 +0100 1727802 http://www.medworm.com/index.php?rid=1156938&cid=t_123598_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHealth%2F%7E3%2F218040975%2F This article was published on Highlight HEALTH. Related articlesLack of Health Insurance Increases Risk of Cancer DeathDecrease in US Cancer DeathsThe Best of Highlight HEALTH 2007 - The Year in ReviewQuitWinLive - The Great American SmokeoutSmoking Duration vs. Intensity and the Impact on Lung Cancer Risk (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=1156938 Thu, 17 Jan 2008 05:48:00 +0100 1156938 http://www.medworm.com/index.php?rid=1003724&cid=t_123598_136_f&fid=36051&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F179836555%2F Bevacizumab is a biologic anti-cancer agent that prevents tumor growth by interfering with the formation of new blood vessels. Now, a new study found that bevacizumab may have the potential to improve the efficacy of standard combination chemotherapy in ovarian cancer. Ovarian cancer or cancer of the ovary is the fifth most common cancer in women and I reckon one of the deadliest. Almost 70% of ovarian cancer patients fail to win against the disease despite chemotherapy. According to Dr. Bram Goldstein, co-author of the study, whose findings are published in Vol. 17 Issue 4 of International Journal of Gynecological Cancer: “The results from our research suggest that the combination of Bevacizumab and standard therapy for the treatment of ovarian cancer may be promising, particularly with... Cancer Commentary blogs http://www.medworm.com/rss/comments.php?id=1003724 Mon, 05 Nov 2007 02:47:01 +0100 1003724